Genmab — December 2017
-
»Nu har vi en tredjelinjebehandling, der holder tre fjerdedele af patienterne i live små tre år efter behandlingsstart. Der er altså tale om patienter, der havde meget dårlige fremtidsudsigter. Så det er ret vildt. Det er virkelig en revolution i behandlingen af myolomatose,« siger Torben Plesner.
-
-
Pas på ikke at overfortolke Stockbull. For at være "sygdomsfri" skal man have CR eller bedre og det havde 44%. 2 års PFS omfattede 69%, men det betyder at deres sygdom ikke er blevet værre - ikke at de er sygdomsfri. Vi ved ikke hvordan de 75% har det blot at de er i live. Abstract: https://ash.confex.com/ash/2017/webprogram/Paper105912.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind